Why control glucose

Keeping blood glucose levels when you suffer from type 2 diabetes saves complications in the kidneys, according to a study that has just been presented at the Annual Congress of the American Diabetes Association (ADA).

Advance's conclusions, an essay on type 2 diabetes for which more than 11,000 patients distributed in centers from 20 countries have been recruited, support intensive control of glucose levels as a strategy to reduce severe complications of metabolic disease by antonomasia.The data, released during the annual meeting of the American Diabetes Association (ADA) include a reduction of 21 percent of neuropathies.

"These results clearly demonstrate that the intensive control of glucose levels, according to the recommendations of most clinical guides, has a determining function in the prevention of renal complications of type 2 diabetes," said Anushka Patel,Responsible for the study and cardiovascular division of the George Institute of International Health."The key message is that the trial is confirmed by the current approach in favor of glucose control, which has had an important effect on the prevention of microvascular complications of diabetes," he added.

Intensive treatment is controversial since the ACCORD study was interrupted in the United States when an increase in the mortality rate of patients treated with this strategy was appreciated.That circumstance has not occurred in the Advance essay.According to Patel, "together, a 10 percent reduction of macro and microvascular complications has been observed, although in reality the latter are the most significant."

The members of the Carlos Abraira team, from the University of Miami, who on Sunday presented a job according to which the risk reduction is not statistically significant in patients with type 2 diabetes, althoughThis second work has focused on cardiovascular episodes.As Abraira himself clarified, "this is a complex study, in which all patients had multiple health problems, including 40 percent of people who had already experienced a previous event.""The goal," he explained, "was to reduce all other risk factors to compare the results only depending on the standard or intensive control of glucose, and that goal has been fulfilled perfectly."

On the other hand, those responsible for the Accord study whose essay had the support of the National Institute of Heart, Lung and Blood (NHLBI), made public the data of their own cohort.According to them, the intensification of glucose control in patients with type 2 diabetes "similar to those included in ACCORD" implies a risk "that clinicians should take into account", in the words of Robert Byington, test coordinator.